25-MAR-2025 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 N 0 Screening 1420 1448 250 118 41 0 0 08/13/2019 330 128
            1448 250 118 41 0 0      
 
    2 Y 1 Lenalidomide   669 120 56 21 1 1 08/13/2019    
        2 Lenalidomide + Daratumumab   658 116 53 18 3 0      
            1327 236 109 39 4 1      
 
    3 Y 3 Stop vs Continue Treatment   252 81 49 30 16 1 08/13/2019    
            252 81 49 30 16 1      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 1 I+R 92 6 6 4 1 0 0 01/05/2022 79 23
        2 I+R+Venetoclax   1 0 0 0 0 0      
        3 V+R   5 5 2 1 0 0      
            12 11 6 2 0 0      
 
  S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Y 1 VRD-R 510 23 18 10 4 1 0 10/12/2023 219 84
        2 DRD-R   24 18 9 4 2 0      
        3 DRD-DR   22 17 9 4 2 0      
            69 53 28 12 5 0      
 
  S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 1 Y 0 Induction 338 11 11 8 6 2 0 07/01/2024 133 42
            11 11 8 6 2 0      
 
    2 Y 1 Dara-VCD   2 2 2 1 1 0 07/01/2024    
        2 Melphalan + ASCT   2 2 2 1 0 0      
            4 4 4 2 1 0      
 
    3 Y 3 Dara   1 1 1 1 1 0 07/01/2024    
            1 1 1 1 1 0      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   52 6 3 2 1 1 05/27/2021 204 81
            52 6 3 2 1 1      
 
    1 E Total Registrations   37 3 1 0 0 0 05/27/2021    
            37 3 1 0 0 0      
 
    2 E Total Registrations   29 14 5 2 0 0 05/27/2021    
            29 14 5 2 0 0      
 
No EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   75 15 4 0 0 0 01/08/2020 235 101
            75 15 4 0 0 0      
 
    1 E Total Registrations   37 11 4 0 0 0 01/08/2020    
            37 11 4 0 0 0      
 

25-MAR-2025 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
S2005 WM, Prev. Untreated, I/R +/- Venetoclax 2 Crossover 24-Jun-21 79 23